摘要
目的:观察厄贝沙坦联合胺碘酮治疗心力衰竭合并心律失常患者的效果。方法:选取100例心力衰竭合并心律失常患者为研究对象,按随机数字表法分为对照组和观察组,每组50例。对照组采用胺碘酮治疗,观察组在对照组基础上联用厄贝沙坦片治疗。比较两组疗效,治疗前后心功能指标[左室射血分数(LVEF)、每搏输出量(SV)、左室舒张期末内径(LVEDD)、左室收缩期末内径(LVESD)]水平,窦性心律维持率和不良反应发生率。结果:观察组治疗总有效率为96.00%,显著高于对照组的74.00%,差异有统计学意义(P<0.05);观察组窦性心律维持率高于对照组,差异有统计学意义(P<0.05);治疗前,两组各心功能指标水平比较,差异均无统计学意义(P>0.05);治疗后,两组LVEF和SV水平均高于治疗前,且观察组高于对照组;两组LVEDD和LVESD水平均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:厄贝沙坦联合胺碘酮治疗心力衰竭合并心律失常患者可提高治疗总有效率和窦性心律维持率,改善心功能指标水平,其效果优于单用胺碘酮治疗效果。
Objective: To observe effects of Irbesartan combined with Amiodarone in treatment of patients with heart failure and arrhythmia. Methods: 100 patients with heart failure and arrhythmia were selected as the research objects, and were divided into control group and observation group according to a random number table, 50 cases in each group. The control group was treated with Amiodarone, while the observation group was treated with Irbesartan tablets on the basis of that of the control group. The effects, levels of cardiac function indexes before and after the treatment [left ventricular ejection fraction(LVEF), stroke volume(SV), left ventricular end diastolic inner diameter(LVEDD), left ventricular end systolic inner diameter(LVESD)], sinus rhythm maintenance rate and incidence of adverse reactions were compared between the two groups. Results: The total effective rate of treatment in the observation group was 96.00%, which was significantly higher than 74.00% in the control group, and the difference was statistically significant(P<0.05). The sinus rhythm maintenance rate in the observation group was higher than that in the control group, and the difference was statistically significant(P<0.05). Before the treatment, there were no statistically significant differences in the levels of cardiac function indexes between the two groups(P>0.05). However, after the treatment, the levels of LVEF and SV of the two groups were higher than those before the treatment, and those of the observation group were higher than those of the control group;the levels of LVEDD and LVESD of the two groups were lower than those before the treatment, and those of the observation group were higher than those of the control group;and the differences were statistically significant Significance(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Irbesartan combined with Amiodarone in the treatment of the patients with heart failure and arrhythmia can increase the tota
作者
关丽丽
GUAN Lili(Department of Cardiology of Sujiatun District Central Hospital,Shenyang 110000 Liaoning,China)
出处
《中国民康医学》
2020年第21期1-2,8,共3页
Medical Journal of Chinese People’s Health
